Kyocera to Purchase Major Assets of Renovis Surgical Technologies
The assets will be transferred into a new California-based company wholly owned by Kyocera International, Inc., to be named Kyocera Medical Technologies, Inc.
Kyocera Corp. recently announced that its U.S. headquarters, Kyocera International, Inc., has finalized an agreement with Renovis Surgical Technologies, Inc., a U.S.-based orthopedic and spinal medical device manufacturer and developer, to purchase the major assets of Renovis’ business operations relating to artificial joint and spinal products. The assets will be transferred into a new California-based company wholly owned by Kyocera International, Inc., to be named Kyocera Medical Technologies, Inc., in March 2019.
Kyocera currently manufactures medical products, including artificial joints and dental implants, primarily for the Japanese market. To grow internationally, Kyocera obtained U.S. FDA 510(k) clearance for its artificial hip joints and began selling them in the U.S. in 2017.
Renovis, founded in 2009, is reportedly a market leader in 3D-printed implants and has developed a broad portfolio of products for the U.S. market, serving the needs of orthopedic, neurological, and trauma surgeons. Renovis has experienced steady growth since its inception and has continued to develop and commercialize a wide range of products manufactured using its Tesera Trabecular Technology, a proprietary implant surface structure made using additive manufacturing. In addition, Renovis has developed an advanced bearing surface technology for joint replacement products.
Kyocera plans to expand its U.S. medical equipment business through this asset purchase. According to the company, the newly established company will develop high value-added products that improve patient health and quality of life through synergies between Kyocera’s proprietary technologies and those purchased from Renovis.